| Regulatory barriers to tissue-engineered products. | |
| | |
MedLine Citation:
|
PMID: 11984990 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Autologous tissue-engineering technology uses the body's own regenerative capacity to solve clinical problems. Human cellular- and tissue-based products include an array of medical products for repair, reproduction, replacement and other therapeutic purposes. However, the lack of European Union regulation for these products is putting the future of the technology at risk in Europe. |
| | |
Authors:
|
E Schutte |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Medical device technology Volume: 13 ISSN: 1048-6690 ISO Abbreviation: Med Device Technol Publication Date: 2002 Mar |
Date Detail:
|
Created Date: 2002-05-02 Completed Date: 2002-05-20 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9215490 Medline TA: Med Device Technol Country: England |
Other Details:
|
Languages: eng Pagination: 27-9 Citation Subset: T |
Affiliation:
|
IsoTis NV, Bilthoven, The Netherlands. eliane.schutte@isotis.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Costs and Cost Analysis European Union Humans International Cooperation Patents as Topic Tissue Banks / legislation & jurisprudence* Tissue Engineering / economics, legislation & jurisprudence* Transplantation, Autologous United States |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cytosteatonecrosis of the newborn infant
Next Document: Maturity-onset diabetes of the young--MODY. Molecular-genetic, pathophysiological and clinical chara...